Navigation Links
Did Sun and Taro Under-Report 3rd Quarter Results by Gaming Reserves?
Date:11/5/2012

NEW YORK, Nov. 5, 2012 /PRNewswire/ -- IsZo Capital Management LP, one of the largest minority shareholders of Taro Pharmaceutical Industries Ltd. (NYSE: TARO), announced today that it delivered the following letter to the Special Committee of the Board of Directors of Taro, citing evidence that raises the question of whether Taro's management may be under-reporting Taro's third quarter net sales data by artificially inflating reserves for product returns, chargebacks, rebates and other sales-related items, just a month ahead of the special meeting of Taro shareholders to vote upon the proposed merger with Sun Pharmaceutical Industries Ltd. (BSE: SUNPHARMA) at the grossly inadequate below-market price of $39.50 per Taro share.

Re:
3rd Quarter Financial Results;
Did Taro Under-Report 3rd Quarter Results by Gaming Reserves? Ladies and Gentlemen:

Recently, rumors have been circulating that Taro and Sun were intentionally trying to understate their financial results by over-reserving; all ahead of the special December 6th shareholder meeting to vote upon the Sun merger.  We have been busy using our forensic accounting skills and broad industry knowledge attempting to evaluate the veracity of these rumors.  To our dismay, Taro and Sun delivered such evidence with the reported 3rd quarter financial results; results suspiciously inconsistent with readily available commercial sources of Taro's prescription and sales data.

Taro's reported financials and IMS's reporting of Taro's sales have had nearly perfect correlation over the last year until Taro's 3rd quarter results.  Based on IMS reported data, Taro should have reported net sales of $176.4 mm vs. the $160.9 mm that Taro reported.  So Taro's results are missing roughly $15.4 mm of sales and a similar amount of EBITDA and Profit.  For example, Taro reported QOQ growth of 1% vs. IMS's 11%.

It's easier to see this in table form, bearing in mind that capture rate ("Capture %") per quarter is defined as IMS reported net sales divided by Taro reported net sales. Differences between IMS and Taro sales should be due to rebates, chargebacks, returns, reserves, etc. Q3 2011Q4 2011Q1 2012Q2 2012Q3 2012IMS Reported Sales ($mm)204,426

216,349

213,840

234,540

260,202Taro Reported Sales ($mm)138,250

148,110

145,140

159,152

160,974Capture %67.63%

68.46%

67.87%

67.86%61.87%Clearly, Taro's recently reported Q3 2012 numbers are inconsistent with the historic correlation between IMS and Taro net sales data, substantiating market rumors that Taro is gaming its reserves for returned products and similar items to artificially deflate net sales data, conveniently, just a month prior to the December 6th special shareholder meeting to vote upon the proposed Sun merger.

Without this apparent change in product reserves, Taro should have reported $176.5 mm of sales and 110.5 mm of EBITDA for the 3rd quarter.  Consistent with underreporting actual financial results, management has also grossly under-forecasted future Taro results.  In Taro's 13E-3, management's projections for the 6 months ended 2012 were EBITDA of $112.9 mm.  Based on IMS sales data, it looks like management will be roughly 100% too low in its 6 month projections.
Even using reported EBITDA, management is 68% too low for its forecast.  Given that Taro management's 6 month 2012 forecast will be between 68% and most likely 100% too low, we don't believe that the Special Committee and Citigroup can rely on management's projections.

Dilip Shanghvi appears tired of being famous and prefers to join the founding Levy family in becoming infamous.  Despite Shanghvi's promises filed publicly several times in SEC 13Ds to protect minority shareholders, Taro's minority shareholders have and continue to face the unprecedented threat of a take under.  In addition, Taro has refused to allow minority shareholders to verify the results of the voting at the December 2011 shareholder meeting, in violation of Israeli law.  To date, IsZo capital and other minority shareholders have not been able to identify any minority shareholders that voted for the indemnification provisions at the December 2011 meeting.  Taro has also refused minority shareholder document requests regarding the Sun merger in violation of Israeli law.  And most egregiously, the Special Committee has relied on a financial advisor that is clearly not independent under Israeli law.  Furthermore, the Special Committee and its non-independent financial advisor continue to rely on financial projections that are clearly wrong.  In addition, despite our diligent efforts, we can't find a single minority shareholder that supports the Sun merger. 

2013 will be the 5th calendar year that IsZo capital and its predecessors will be Taro shareholders.  We are more excited than ever on Taro's future.  Taro is currently the #1 Generic Dermatology Company in the U.S.; and the recent EU-Israel legislation doubles the market opportunity available to Taro without almost any additional cost.  We are very confident that in the long term, great financial reward will accrue to Taro's minority shareholders if the Sun merger offer is rejected.

Sincerely,/s/ Brian SheehyBrian Sheehy

Managing Partner, IsZo Capital 


'/>"/>
SOURCE IsZo Capital Management LP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ADVENTRX Reports Third Quarter 2012 Financial Results
2. Endo Reports Third Quarter Financial Results And Updates 2012 Financial Guidance
3. Valeant Pharmaceuticals Reports 2012 Third Quarter Financial Results
4. Thoratec Reports Third Quarter Results
5. IRIDEX Reports 2012 Third Quarter Results
6. Masimo Reports Third Quarter 2012 Financial Results; Board Declares Special Cash Dividend of $1.00 per Share
7. Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results
8. MAP Pharmaceuticals Reports Third Quarter of 2012 Financial Results
9. Halozyme to Host Third Quarter Financial Results Conference Call
10. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012
11. PDL BioPharma to Announce Third Quarter 2012 Financial Results on November 5, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
Breaking Medicine News(10 mins):